Investment Rating - The report maintains a "Buy-A" investment rating for the company [5][6]. Core Views - The company achieved rapid growth in H1 2024, with revenue reaching 892 million yuan, a year-on-year increase of 30.10%, and a net profit of 169 million yuan, up 92.95% year-on-year [2][3]. - The core product, 0.01% atropine sulfate eye drops, has been approved and is expected to see sustained sales growth due to a large potential market among children with myopia [4][5]. - The company is actively conducting clinical trials for 0.02% and 0.04% atropine sulfate eye drops, which will help meet the treatment needs of patients with varying degrees of myopia [4]. Financial Summary - For H1 2024, the revenue breakdown includes gel/eye ointment at 176 million yuan (-0.58%), eye drops at 512 million yuan (+62.97%), and medical services at 164 million yuan (+5.44%) [3]. - The projected net profits for 2024 to 2026 are estimated at 500 million yuan, 644 million yuan, and 760 million yuan respectively, with an expected EPS of 2.86 yuan per share for 2024 [5][9]. - The company's total market capitalization is approximately 17.44 billion yuan, with a circulating market value of about 13.40 billion yuan [6]. Price Target - The report sets a 6-month target price of 114.40 yuan per share, based on a 40x PE ratio [5][6].

2024 年 08 月 29 日 比亚迪(002594.SZ) 比亚迪发布 2024 年中报：2024Q2 公司实现归母净利润 90.6 亿元、同比 +32.8%、环比+98.4%；实现扣非净利润 85.6 亿元、同比+39.7%、环比 +128.2%。2024H1 实现归母净利润 136.3 亿元、同比+24.4%，扣非后归母 净利润 123.15 亿元、同比+27.0%。 销量增长驱动收入稳定增长，销售结构变化下 ASP 和毛利率略有下滑。 2024Q2 公司实现营收 1761.8 亿元，同比+25.9%、环比+41.0%； 1）量：2024Q2 公司乘用车销售 98 万辆，同比+40%、环比+57% ; 2）价：2024Q2 单车 ASP 为 13.65 万元，同比/环比分别-2.1/-0.5 万元， 我们认为主要来自销售结构的变化：①荣耀版车型销售占比提升；②出海 销量占比下降：Q2 公司共出口乘用车 10.6 万辆、环比+8%，占比 11%/- 5pct；③高端车型占比下滑：Q2 公司方程豹+腾势+仰望三大品牌共销售 4.5 万辆、环比+16%，占比 5%/-1pct。 3）利：2024Q2 公司汽 ...

2024 年 08 月 28 日 凯莱英(002821.SZ) 事件： 剔除去年同期大订单影响，2024H1 营收实现正增长： 新签订单及时回暖，公司各板块业务稳健经营： 得益于全球创新药投融资的改善，以及多肽、ADC 等景气赛道的研发 需求提振，2024H1 公司新签订单同比增长超过 20%，在手订单总额达 9.7 亿美元。公司新签订单逐步回暖，驱动各板块业务稳步发展。其 中，小分子业务方面，2024H1 公司交付商业化项目和新增商业化项 目分别为 43 个和 9 个，商业化阶段 CDMO 收入剔除大订单影响后同 比增长 8.82%；新兴业务方面，多肽业务持续快速发展，公司获得多 个跨国制药公司的多肽临床中后期项目，且助力国内客户 GLP-1 多 肽项目动态核查顺利通过。为满足客户多肽商业化生产需求，公司积 极扩建相关产能，2024 年中多肽固相合成总产能达 14,250L。此外， 公司依托在毒素-连子领域的丰富项目经验和专业能力，快速建设一 站式 ADC 服务能力，截至 2024H1，生物大分子业务在手订单接近百 余个，ADC 项目占比总订单数量超过 50%。 投资建议： 预计 2024 年-2026 年 ...

Investment Rating - The investment rating for the company is maintained at "Buy-A" with a target price of 48.44 CNY for the next six months, based on a projected P/E ratio of 20 times for 2024 [4][2]. Core Views - The company is experiencing short-term operational pressure but is expected to improve in the future as it expands its product categories and continues to grow in overseas markets. The revenue is anticipated to recover rapidly [1][2]. - In the first half of 2024, the company reported a revenue of 2.13 billion CNY, a year-on-year decrease of 9.0%, and a net profit attributable to shareholders of 160 million CNY, down 32.0% year-on-year [1]. - The second quarter of 2024 saw a revenue of 940 million CNY, reflecting a year-on-year decline of 14.0%, with a net profit of 10 million CNY, down 85.9% year-on-year [1]. Financial Performance Summary - The company's revenue in 2024 is projected to be 4.71 billion CNY, with net profit expected to be 450 million CNY, and EPS forecasted at 2.42 CNY [3][9]. - The company’s overseas revenue grew by 27% year-on-year in the first half of 2024, indicating strong growth momentum in international markets [1]. - The gross profit margin decreased by 1.0 percentage points year-on-year in Q2 2024, while the net profit margin fell by 5.5 percentage points year-on-year, primarily due to increased R&D and management expenses [1][6]. Revenue and Profitability Trends - The overall retail sales of kitchen small appliances in China decreased by 5% year-on-year in the first half of 2024, contributing to the decline in the company's revenue [1]. - The average selling price of the company's products dropped by 14% year-on-year in Q2 2024, with online sales on major platforms like Taobao, JD, and Douyin experiencing declines of 9%, 29%, and 55% respectively [1]. - The company’s operating cash flow in Q2 2024 decreased by 310 million CNY year-on-year, attributed to rising raw material costs and declining sales revenue [1][6].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 157.41 CNY, while the current stock price is 123.00 CNY as of August 28, 2024 [6][12]. Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2024, with revenue reaching 1.267 billion CNY, a year-on-year increase of 26.22%, and net profit of 129 million CNY, a year-on-year increase of 3.64% [4][5]. - In Q2 2024, the company achieved a revenue of 795 million CNY, a year-on-year increase of 32.22% and a quarter-on-quarter increase of 68.53%, with net profit reaching 119 million CNY, a year-on-year increase of 67.43% and a quarter-on-quarter increase of 1032.79% [4][5]. - The company has a strong order backlog, with contract liabilities increasing by 47% quarter-on-quarter to 2.038 billion CNY, indicating robust demand for its products [5][6]. Financial Performance Summary - For H1 2024, the company reported R&D expenses of 314 million CNY, accounting for 24.81% of revenue, reflecting a commitment to innovation and product development [6][12]. - The company expects revenue growth to continue, projecting revenues of 4.058 billion CNY, 5.275 billion CNY, and 6.593 billion CNY for 2024, 2025, and 2026 respectively, with net profits of 826.6 million CNY, 1.0076 billion CNY, and 1.3955 billion CNY for the same years [12][15]. - The company has maintained a high level of R&D investment, focusing on new products and processes, which have been validated by clients and are contributing to industrial applications [6][11].

本报告仅供 Choice 东方财富 使用，请勿传阅。 2024 年 08 月 29 日 统联精密(688210.SH) 公司快报 行业复苏带动业绩高增，持续研发投入成 长可期 事件： 公司发布 2024 年半年度报告，2024H1 公司实现营业收入 3.65 亿元， 同比增长75.49%；公司实现归母净利润4144万元，同比增长304.99%。 其中 24Q2 单季度，公司实现营业收入 2.36 亿元，同比增长 69.28%， 环比增长 81.39%；归母净利润 2677 万元，同比增长 103.61%，环比 增长 82.43%。公司 24Q2 实现单季度毛利率 41.19%，同比增长 7.56 个 pct，环比增长 0.80 个 pct。 平板行业需求回暖，折叠手机市场持续高增，推动业绩高增： 2024H1，受益平板行业复苏、大客户新品上量带动的销量提升以及折 叠屏手机市场持续高增，公司 MIM 产品及其他金属工艺制品业务均 取得了高速增长。其中 MIM 产品实现收入 1.73 亿元，同比增长 39.91%；其他金属工艺制品取得收入 1.78 亿元，同比增长 152.47%， 并首次超越 MIM 产品收入， ...

Investment Rating - The investment rating for the company is "Buy - A" with a target price of 26 CNY for the next six months [3]. Core Views - The company's performance in the first half of 2024 shows a revenue growth rate of 7.13%, with a pre-provision profit growth of 10.12% and a net profit growth of 5.42%, indicating stable performance in line with expectations [1][9]. - The growth in net profit in the second quarter was primarily driven by asset expansion and a decrease in the cost-to-income ratio, while non-interest income growth slowed down and tax expenses increased, which were the main detractors from performance [1][9]. - The company has maintained a strong asset expansion, with a year-on-year growth of 18.43% in interest-earning assets in the second quarter, reflecting its leading position in the banking sector [1][9]. Summary by Sections Financial Performance - In the second quarter, the company's net interest margin was 1.85%, showing a slight year-on-year decline of 1 basis point, which is better than peers [2][7]. - The average yield on interest-earning assets decreased by 11 basis points to 3.99%, influenced by the decline in LPR and insufficient effective credit demand [2][7]. - Non-interest income decreased by 6.9% year-on-year, with a significant drop in net commission income by 27.1%, primarily due to lower insurance agency fees and a decline in wealth management-related income [7][9]. Asset Quality - The non-performing loan (NPL) ratio stood at 0.76% at the end of the first quarter, with a notable increase in retail credit risk, as the retail NPL ratio rose to 1.67% [7][9]. - The annualized NPL generation rate for the first half of the year was 1.2%, up 38 basis points year-on-year, indicating a high level of NPL generation [8][9]. - The provision coverage ratio decreased to 420.55%, reflecting a decline in the provisioning ratio [8][9]. Future Outlook - The company is expected to achieve a revenue growth rate of 6.49% and a net profit growth rate of 4.77% for 2024, supported by a significant increase in reclassified other comprehensive income [9][10]. - The report suggests that the valuation of the bank has reached historical lows, indicating that a more optimistic outlook may be warranted moving forward [9].

2024 年 08 月 28 日 云铝股份(000807.SZ) 提升 公司发布 2024 年中报 电解铝 Q2 产量环比上升，铝价上涨增厚利润 公司主要生产经营目标不变 2024 年公司主要生产经营目标为，氧化铝产量约 140 万吨（已完成 51.6%），电解铝产量约 270 万吨（已完成 50%），铝合金及加工产品 产量约 126 万吨（已完成 46.6%），炭素制品产量约 80 万吨（已完 成 49.7%）。 拟派发中期分红回馈股东 公司经第九届董事会第六次会议审议通过的 2024 年中期利润分配预 案为以总股本 34.68 亿股为基数，向全体股东每 10 股派发现金红利 | --- | --- | |-------------------|--------------------| | | 公司快报 | | | | | | 证券研究报告 | | | 铝 | | 投资评级 | 买入-A | | | 维持评级 | | 6 个月目标价 | 13.8 元 | | 股价 (2024-08-27) | 12.01 元 | | 交易数据 | | | 总市值(百万元 | ) 41,650.17 | | 流通市值 | ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 4.83 CNY, which represents a 2x PS valuation for 2024 [5][8]. Core Views - The company is expected to achieve a turnaround from losses to profitability, driven by significant improvements in operational metrics and revenue growth [4][8]. - The company's revenue for the first half of 2024 reached 2.42 billion CNY, a year-on-year increase of 9.53%, while the net profit attributable to shareholders was a loss of 174 million CNY, a reduction in loss by 21.89% [2][4]. Financial Performance - In H1 2024, the total outpatient and emergency service volume was 1.25 million visits, up 17.15% year-on-year, and inpatient service volume was 100,300 visits, up 16.76% [3]. - The company's two core hospitals showed significant revenue and operational improvements, with Xi'an Gaoxin Hospital achieving a revenue of 772 million CNY, a growth of 8.69%, and a net profit of 49.46 million CNY, up 43.63% [3]. - Xi'an International Medical Center Hospital reported a revenue of 1.63 billion CNY, a growth of 14.68%, with a net loss of 78.27 million CNY, reducing losses by 49.29% [3]. Profitability Metrics - The overall gross margin improved to 9.49%, an increase of 1.73 percentage points year-on-year, while the non-recurring net profit margin improved to -5.74%, an increase of 5.79 percentage points [4]. - Management expenses decreased to 11.52% of revenue, down 1.56 percentage points year-on-year, and financial expenses decreased to 3.66%, down 1.37 percentage points [4]. Future Projections - Revenue projections for 2024 to 2026 are 5.46 billion CNY, 6.28 billion CNY, and 7.07 billion CNY respectively, with net profits expected to improve significantly by 2026 [8][9]. - The company is anticipated to achieve a net profit of 1.95 billion CNY in 2025 and 3.70 billion CNY in 2026, indicating a strong recovery trajectory [8][9].

Investment Rating - The report assigns a "Buy-A" rating to Yiling Pharmaceutical (002603 SZ) with a 6-month target price of 17 00 yuan, implying a 25x forward P/E ratio for 2024 [6][10] Core Views - Yiling Pharmaceutical's H1 2024 performance was under pressure due to high base effects from the previous year, with revenue declining 32 19% YoY to 4 604 billion yuan and net profit dropping 66 97% YoY to 530 million yuan [2][3] - The company's cardiovascular drug sales fell 7 86% YoY to 2 314 billion yuan, while respiratory drug sales plunged 58 42% YoY to 1 284 billion yuan due to lower demand and high inventory levels [3] - Gross margin declined 8 37 percentage points YoY to 53 37% in H1 2024, mainly due to rising raw material costs and lower capacity utilization [4] - R&D investment remained strong at 411 million yuan, accounting for 8 92% of revenue, with several innovative drugs in the pipeline [5][9] Financial Performance - Q2 2024 revenue declined 27 10% YoY to 2 082 billion yuan, with net profit down 43 86% YoY to 227 million yuan [2] - Operating margin fell to 14 9% in H1 2024 from 17 2% in 2023, while net margin dropped to 11 6% from 13 1% [11] - The company's ROE declined to 9 3% in H1 2024 from 11 8% in 2023, reflecting weaker profitability [11] Product Pipeline - Yiling Pharmaceutical has 2 innovative drugs in the NDA stage (Qifang Bitong Tablets and Chaihuang Lidan Capsules) and 2 in Phase III clinical trials (Luobitong Tablets and Pediatric Lianhua Qinggan Granules) [9] - The company has 4 innovative drugs in Phase II clinical trials, covering cardiovascular, respiratory, and other therapeutic areas [9] Valuation - The report forecasts 2024-2026 revenue of 9 856 billion yuan, 11 152 billion yuan, and 12 447 billion yuan, respectively [10] - Net profit is expected to grow to 1 139 billion yuan in 2024, 1 434 billion yuan in 2025, and 1 689 billion yuan in 2026 [10] - The stock trades at 22 2x 2024E P/E, 17 7x 2025E P/E, and 15 0x 2026E P/E [10][11]